Oncology ASCO 2025: Breast cancer breakthroughs drive HCPs’ online co... Every year at ASCO, we see new data. New combinations. New standards of care.
Sales & Marketing ASCO unpacked: Signals for optimising healthcare comms Earlier this month, more than 45,000 oncology stakeholders convened at the American Society of Clinical Oncology (ASCO) congress in Chicago to share, learn, and debate the latest cutting-ed
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.